The Anand Spine Group in Los Angeles is participating in an Investigational Device Exemption study examining two cervical total disc replacement devices, according to a Jan. 21 announcement published by Patch.
Five things to know:
1. Sponsored by Centinel Spine and monitored by the FDA, the study will evaluate the prodisc C Vivo and prodisc C SK devices' safety and effectiveness in treating two-level symptomatic cervical disc disease. The devices will be compared with an FDA-approved total disc replacement device.
2. In use since 2009, the prodisc C Vivo is the most commonly implanted total disc replacement product outside of the U.S.
3. The prodisc C SK is a variation of the prodisc C Nova implant, which has been implanted outside the U.S. for about a decade.
4. The study will involve participants between the ages of 18 and 69 who show signs of symptomatic cervical disc disease or other potential spinal conditions.
5. Neel Anand, MD, an orthopedic surgery professor and the director of spine trauma at Los Angeles-based Cedars-Sinai Medical Center, will serve as the Anand Spine Group's lead investigator in the study.